

Mario A Eisenberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6600539/publications.pdf>

Version: 2024-02-01

65
papers

9,216
citations

159585

30
h-index

118850

62
g-index

67
all docs

67
docs citations

67
times ranked

9766
citing authors

#	ARTICLE	IF	CITATIONS
1	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸ F-DCFPyL. <i>Molecular Imaging</i> , 2022, 2022, 7056983.	1.4	6
2	Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHARTED E3805. <i>Prostate</i> , 2022, 82, 1176-1185.	2.3	2
3	Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211000.	3.2	4
4	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 447-455.	5.4	52
5	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021, 79, 692-699.	1.9	49
6	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 387-395.	0.8	19
7	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	1.9	61
8	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted ¹⁸ F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1430-1437.	5.0	24
9	Nivolumab plus ipilimumab, with or without enzalutamide, in AR ⁺ expressing metastatic castration-resistant prostate cancer: A phase 2 nonrandomized clinical trial. <i>Prostate</i> , 2021, 81, 326-338.	2.3	35
10	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , 2021, 144, 302-309.	2.8	29
11	Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. <i>Cancers</i> , 2021, 13, 1284.	3.7	6
12	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382.	1.6	65
13	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021, 30, 47-62.	0.4	2
14	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. <i>Journal of Urology</i> , 2021, 206, 623-629.	0.4	4
15	Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. <i>European Journal of Cancer</i> , 2020, 125, 142-152.	2.8	7
16	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , 2020, 20, 492.	2.6	16
17	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 650.	7.1	696
18	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. <i>Human Pathology</i> , 2020, 101, 70-79.	2.0	5

#	ARTICLE	IF	CITATIONS
19	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 948-956.	0.8	37
20	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019, 19, 572.	2.6	3
21	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. <i>Human Pathology</i> , 2019, 87, 95-102.	2.0	34
22	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	23
23	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , 2019, 76, 452-458.	1.9	109
24	Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer – Playing the Right CARD. <i>New England Journal of Medicine</i> , 2019, 381, 2564-2566.	27.0	5
25	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. <i>World Journal of Urology</i> , 2019, 37, 2623-2629.	2.2	21
26	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 44-60.	1.9	48
27	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 76-86.	10.7	149
28	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-382.	1.6	75
29	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , 2018, 9, 28561-28571.	1.8	129
30	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. <i>European Urology</i> , 2017, 71, 740-747.	1.9	256
31	MSH2 Loss in Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6863-6874.	7.0	122
32	A phase II randomized trial of Observation versus stereotactic ablative Radiation for OLigometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , 2017, 17, 453.	2.6	83
33	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m ²) and the Currently Approved Dose (25 mg/m ²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer – PROSELICA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3198-3206.	1.6	218
34	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3181-3188.	1.6	73
35	Detection fidelity of AR mutations in plasma derived cell-free DNA. <i>Oncotarget</i> , 2017, 8, 15651-15662.	1.8	20
36	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 411-419.	2.6	202

#	ARTICLE	IF	CITATIONS
37	Bipolar Androgen Therapy for Men With Androgen Ablation Na ⁺ ve Prostate Cancer: Results From the Phase II BATMAN Study. <i>Prostate</i> , 2016, 76, 1218-1226.	2.3	63
38	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. <i>Prostate</i> , 2016, 76, 512-520.	2.3	19
39	Comparison of Prostate-Specific Membrane Antigen-Based ¹⁸ F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Na ⁺ ve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 46-53.	5.0	111
40	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. <i>Prostate</i> , 2015, 75, 1518-1525.	2.3	88
41	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 582.	7.1	552
42	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	12.4	205
43	AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 138-138.	1.6	14
44	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.. <i>Journal of Clinical Oncology</i> , 2015, 33, 336-336.	1.6	3
45	Metformin use and outcome of sunitinib treatment in diabetic patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 440-440.	1.6	1
46	Patients with metastatic chromophobe renal cell carcinoma treated with sunitinib therapy: Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 429-429.	1.6	0
47	A retrospective analysis of the effect of time from diagnosis to cystectomy on survival in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 360-360.	1.6	2
48	Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. <i>Urology</i> , 2014, 83, 1444.e1-1444.e6.	1.0	19
49	Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. <i>Nature</i> , 2014, 515, 134-137.	27.8	284
50	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1028-1038.	27.0	2,233
51	Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study. <i>European Urology</i> , 2014, 66, 330-336.	1.9	48
52	Maximal Testosterone Suppression in Prostate Cancer—Free vs Total Testosterone. <i>Urology</i> , 2014, 83, 1217-1222.	1.0	16
53	The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 44-44.	1.6	2
54	Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local therapy (tx).. <i>Journal of Clinical Oncology</i> , 2013, 31, 160-160.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D).. Journal of Clinical Oncology, 2013, 31, 146-146.	1.6	0
56	Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?. Journal of Clinical Oncology, 2013, 31, 458-458.	1.6	0
57	Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su).. Journal of Clinical Oncology, 2012, 30, e15058-e15058.	1.6	1
58	Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model.. Journal of Clinical Oncology, 2012, 30, 37-37.	1.6	1
59	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 2008, 26, 1148-1159.	1.6	1,960
60	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology, 2004, 63, 114-119.	1.0	19
61	Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone. Journal of Clinical Oncology, 2000, 18, 1440-1450.	1.6	176
62	COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?. Journal of Urology, 2000, 164, 3-9.	0.4	100
63	The experience with suramin in advanced prostate cancer. Cancer, 1995, 75, 1927-1934.	4.1	10
64	Southwest oncology group strategies in prostatic carcinoma. Journal of Surgical Oncology, 1995, 11, 60-64.	1.4	9
65	Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Medicine, 1995, 1, 944-949.	30.7	590